Immunogen (IMGN) 13.99 $IMGN
Zogenix Shares Soar on Massachusetts Developments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:30PM CDT
Zogenix announced that the U.S. District Court in Massachusetts has entered an order preventing a ban on Zohydro ER on Constitutional grounds.
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2014 Financial Results
Business Wire - Thu Apr 17, 3:20PM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 25, 2014, to discuss ImmunoGen's financial results for the three-month period ended March 31, 2014. Management also will provide an update on the Company.
Strength Seen in Apricus Biosciences (APRI): Stock Soars 18.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 8:04AM CDT
Apricus Biosciences, Inc. was a big mover last session, as the company saw its shares rise almost 19% on the day.
ImmunoGen, Inc. (IMGN) in Focus: Stock Rallies 11% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:44AM CDT
ImmunoGen, Inc. was a big mover last session, as the company saw its shares surge 11% on the day.
Why Zogenix, ImmunoGen, and voxeljet Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 4:26PM CDT
If you haven't noticed, earnings season is starting to kick into full swing, and investors apparently like what they're seeing thus far, with the broad-based S&P 500 surging to its third consecutive gain. In addition to a number of positive...
Nasdaq stocks posting largest percentage increases
AP - Wed Apr 16, 12:31PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Why ImmunoGen Inc. Shares Took Flight
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 12:13PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ImmunoGen , a biopharmaceutical company...
Pharmacyclics (PCYC) Crumbles: Stock Falls by 7.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 10:00AM CDT
Pharmacyclics’ shares fell by nearly 8% yesterday, continuing its downtrend in the past one-month time frame.
Immunogen Shares Down 11.7% Since SmarTrend's Sell Call (IMGN)
Comtex SmarTrend(R) - Mon Apr 14, 9:23AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on March 28th, 2014 at $14.85. In approximately 2 weeks, Immunogen has returned 11.72% as of today's recent price of $13.11.
ImmunoGen Up on Positive Pipeline Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:00PM CDT
ImmunoGen's shares have been up over a couple of trading sessions following positive pipeline results.
Regulatory Update from Forest Labs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 3:40PM CDT
Forest Labs and partner Almirall announced that the FDA has provided a feedback on their new drug application (NDA) for the fixed dose combination of Tudorza (aclidinium) and formoterol.
Pre-Market Scans on Top Gainers -- Research on Athlon Energy, Venaxis, Desarrolladora Homex, and ImmunoGen
PR Newswire - Thu Apr 10, 12:30PM CDT
On Wednesday, April 09, 2014, the US markets saw a positive sentiment, as the NASDAQ Composite closed at 4,183.90, up 1.72%, the Dow Jones Industrial Average ended the session at 16,437.18, up 1.11%, and the S&P 500 edged 1.09% higher to finish the trading session at 1,872.18. The session saw a positive impact from Information Technology, Health Care and Materials sectors along with a drag from Utilities and Telecommunication Services sectors. A number of stocks saw large movements, including Athlon Energy Inc. (NYSE: ATHL), Venaxis Inc. (NASDAQ: APPY), Desarrolladora Homex S.A.B. de C.V. (NYSE: HXM) and ImmunoGen Inc. (NASDAQ: IMGN). Free technical research on ATHL, APPY, HXM and IMGN can be downloaded upon signing up at:
Pacira Prices Offering, Shares Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 11:00AM CDT
Shares of Pacira Pharmaceuticals soared 11.3% on the news of the pricing of the common stock at an offer price of $64.00 per share.
ImmunoGen, Inc. Announces First Clinical Findings with Refined Dosing Strategy for IMGN853
Business Wire - Tue Apr 08, 3:15PM CDT
--Data Presented at American Association for Cancer Research Annual Meeting
Earnings Release and Presentation Schedules, Nominations, and Financial Results - Analyst Notes on Five Prime Therapeutics, Acceleron, Emergent BioSolutions, CONMED, and ImmunoGen
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Five Prime Therapeutics, Inc. (NASDAQ: FPRX), Acceleron Pharma Inc. (NASDAQ: XLRN), Emergent BioSolutions Inc. (NYSE: EBS), CONMED Corporation (NASDAQ: CNMD), and ImmunoGen, Inc. (NASDAQ: IMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
ImmunoGen, Inc. Announces Presentations by Company Scientists at Upcoming AACR Annual Meeting
Business Wire - Mon Mar 17, 10:30AM CDT
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentations scheduled to be made by Company scientists at the American Association for Cancer Research (AACR) Annual Meeting to be held April 5-9, 2014 in San Diego, CA.
IDEXX Laboratories Elects Daniel Junius to Board of Directors
PR Newswire - Tue Mar 11, 3:15PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX), today announced the unanimous election of Daniel M. Junius as a member of the Company's Board of Directors, effective March 11, 2014. Mr. Junius fills a vacancy on the Board for a Class I director, the remaining term for which ends at the Company's 2015 annual meeting of stockholders.
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
Business Wire - Thu Feb 27, 3:39PM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
ImmunoGen, Inc. (IMGN) Catches Eye: Stock Jumps 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 7:44AM CST
ImmunoGen, Inc. was a big mover last session, as the company saw its shares rise a little over 6% on the day.
ImmunoGen, Inc. Appoints Ellie Harrison as Chief Human Resources Officer
Business Wire - Thu Feb 20, 5:30AM CST
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, today announced the appointment of Ellie Harrison as Vice President and Chief Human Resources Officer. Ms. Harrison brings to ImmunoGen more than thirty years of senior level Human Resources (HR) experience. She reports to Daniel Junius, President and Chief Executive Officer of ImmunoGen.
Zogenix Shares Soar on Massachusetts Developments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:30PM CDT
Zogenix announced that the U.S. District Court in Massachusetts has entered an order preventing a ban on Zohydro ER on Constitutional grounds.
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2014 Financial Results
Business Wire - Thu Apr 17, 3:20PM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 25, 2014, to discuss ImmunoGen's financial results for the three-month period ended March 31, 2014. Management also will provide an update on the Company.
Strength Seen in Apricus Biosciences (APRI): Stock Soars 18.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 8:04AM CDT
Apricus Biosciences, Inc. was a big mover last session, as the company saw its shares rise almost 19% on the day.
ImmunoGen, Inc. (IMGN) in Focus: Stock Rallies 11% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:44AM CDT
ImmunoGen, Inc. was a big mover last session, as the company saw its shares surge 11% on the day.
Why Zogenix, ImmunoGen, and voxeljet Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 4:26PM CDT
If you haven't noticed, earnings season is starting to kick into full swing, and investors apparently like what they're seeing thus far, with the broad-based S&P 500 surging to its third consecutive gain. In addition to a number of positive...
Nasdaq stocks posting largest percentage increases
AP - Wed Apr 16, 12:31PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Why ImmunoGen Inc. Shares Took Flight
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 12:13PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ImmunoGen , a biopharmaceutical company...
Pharmacyclics (PCYC) Crumbles: Stock Falls by 7.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 10:00AM CDT
Pharmacyclics’ shares fell by nearly 8% yesterday, continuing its downtrend in the past one-month time frame.
Immunogen Shares Down 11.7% Since SmarTrend's Sell Call (IMGN)
Comtex SmarTrend(R) - Mon Apr 14, 9:23AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on March 28th, 2014 at $14.85. In approximately 2 weeks, Immunogen has returned 11.72% as of today's recent price of $13.11.
ImmunoGen Up on Positive Pipeline Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:00PM CDT
ImmunoGen's shares have been up over a couple of trading sessions following positive pipeline results.
Regulatory Update from Forest Labs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 3:40PM CDT
Forest Labs and partner Almirall announced that the FDA has provided a feedback on their new drug application (NDA) for the fixed dose combination of Tudorza (aclidinium) and formoterol.
Pre-Market Scans on Top Gainers -- Research on Athlon Energy, Venaxis, Desarrolladora Homex, and ImmunoGen
PR Newswire - Thu Apr 10, 12:30PM CDT
On Wednesday, April 09, 2014, the US markets saw a positive sentiment, as the NASDAQ Composite closed at 4,183.90, up 1.72%, the Dow Jones Industrial Average ended the session at 16,437.18, up 1.11%, and the S&P 500 edged 1.09% higher to finish the trading session at 1,872.18. The session saw a positive impact from Information Technology, Health Care and Materials sectors along with a drag from Utilities and Telecommunication Services sectors. A number of stocks saw large movements, including Athlon Energy Inc. (NYSE: ATHL), Venaxis Inc. (NASDAQ: APPY), Desarrolladora Homex S.A.B. de C.V. (NYSE: HXM) and ImmunoGen Inc. (NASDAQ: IMGN). Free technical research on ATHL, APPY, HXM and IMGN can be downloaded upon signing up at:
Pacira Prices Offering, Shares Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 11:00AM CDT
Shares of Pacira Pharmaceuticals soared 11.3% on the news of the pricing of the common stock at an offer price of $64.00 per share.
ImmunoGen, Inc. Announces First Clinical Findings with Refined Dosing Strategy for IMGN853
Business Wire - Tue Apr 08, 3:15PM CDT
--Data Presented at American Association for Cancer Research Annual Meeting
Earnings Release and Presentation Schedules, Nominations, and Financial Results - Analyst Notes on Five Prime Therapeutics, Acceleron, Emergent BioSolutions, CONMED, and ImmunoGen
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Five Prime Therapeutics, Inc. (NASDAQ: FPRX), Acceleron Pharma Inc. (NASDAQ: XLRN), Emergent BioSolutions Inc. (NYSE: EBS), CONMED Corporation (NASDAQ: CNMD), and ImmunoGen, Inc. (NASDAQ: IMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
ImmunoGen, Inc. Announces Presentations by Company Scientists at Upcoming AACR Annual Meeting
Business Wire - Mon Mar 17, 10:30AM CDT
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentations scheduled to be made by Company scientists at the American Association for Cancer Research (AACR) Annual Meeting to be held April 5-9, 2014 in San Diego, CA.
IDEXX Laboratories Elects Daniel Junius to Board of Directors
PR Newswire - Tue Mar 11, 3:15PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX), today announced the unanimous election of Daniel M. Junius as a member of the Company's Board of Directors, effective March 11, 2014. Mr. Junius fills a vacancy on the Board for a Class I director, the remaining term for which ends at the Company's 2015 annual meeting of stockholders.
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
Business Wire - Thu Feb 27, 3:39PM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
ImmunoGen, Inc. (IMGN) Catches Eye: Stock Jumps 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 7:44AM CST
ImmunoGen, Inc. was a big mover last session, as the company saw its shares rise a little over 6% on the day.
ImmunoGen, Inc. Appoints Ellie Harrison as Chief Human Resources Officer
Business Wire - Thu Feb 20, 5:30AM CST
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, today announced the appointment of Ellie Harrison as Vice President and Chief Human Resources Officer. Ms. Harrison brings to ImmunoGen more than thirty years of senior level Human Resources (HR) experience. She reports to Daniel Junius, President and Chief Executive Officer of ImmunoGen.
